Presentation is loading. Please wait.

Presentation is loading. Please wait.

Disease B A C SUPPLEMENTARY FIGURE 1 Molecular Function D.

Published byKristina Parsons Modified over 8 years ago

Similar presentations

Presentation on theme: "Disease B A C SUPPLEMENTARY FIGURE 1 Molecular Function D."— Presentation transcript:

1 Disease B A C SUPPLEMENTARY FIGURE 1 Molecular Function D

2 SUPPLEMENTARY FIGURE 2 A B C E D

3 AB OVCAR8 SKOV3 C D E OVCAR8SKOV3 SUPPLEMENTARY FIGURE 3

4 D E FG Paclitaxel (1µM)Gemcitabine (2µM) PEO4 (10µM)PEO4 (25µM) siControlsiLARP1 (1)siLARP1 (2) A B C SKOV3 Paclitaxel (1µM) Gemcitabine (2µM) SUPPLEMENTARY FIGURE 4

5 SKOV3 OVCAR8 HeLa A B SUPPLEMENTARY FIGURE 5 siControlsiLARP1 (1)siLARP1 (2)

6 OVCAR3IGROV-1 HeLa A B Cell lineMean CD133+ population on flow cytometry NCI60 relative expression (probe intensity – dataset minimum) SKOV3<0.1% 0 OVCAR8<0.1% 0 OVCAR35.9% 4.56 IGROV14.6% 4.71 SUPPLEMENTARY FIGURE 6

7 A B D C F Benign mucinous Mucinous carcinoma E G SUPPLEMENTARY FIGURE 7

Download ppt "Disease B A C SUPPLEMENTARY FIGURE 1 Molecular Function D."

Similar presentations

SKOV-3, 48h CaOV-3, 48h BG-1, 48h Concentration (µM) Viable cells (%) SW 43 SW IV-52s SW III-123 SW 43 + SW IV-52s SW 43 SW IV-52s SW III-123 SW 43 + SW.

SKOV-3, 48h CaOV-3, 48h BG-1, 48h Concentration (µM) Viable cells (%) SW 43 SW IV-52s SW III-123 SW 43 + SW IV-52s SW 43 SW IV-52s SW III-123 SW 43 + SW.
Supplementary Data shLuc sh14-3-3   sh14-3-3  179 shLuc sh14-3-3   sh14-3-3  179 Asyn Noco 2.1% 6.1% 2.4% 16.5%11.4%1.1% 5.9%3.9%2.5% 52.5%10.0%4.9%

Supplementary Data shLuc sh   sh  179 shLuc sh   sh  179 Asyn Noco 2.1% 6.1% 2.4% 16.5%11.4%1.1% 5.9%3.9%2.5% 52.5%10.0%4.9%
AB 11 22 33 44 55 66 77 88 99 10  20  19  18  17  16  15  14  13  12  11  21  22  23  24  25  26  27  28.

AB 11 22 33 44 55 66 77 88 99 10  20  19  18  17  16  15  14  13  12  11  21  22  23  24  25  26  27  28.
Legends for supplementary figures Fig s1. A: Western blot showing the suppression of SRp20 expression by Dox induction of SRp20 siRNAs in SKOV3 sublines.

Legends for supplementary figures Fig s1. A: Western blot showing the suppression of SRp20 expression by Dox induction of SRp20 siRNAs in SKOV3 sublines.
Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.

Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Supplemental Figure 1 A. EpCAM Gating Strategy Top Row: Histogram showing unstained BT474 cells with low fluorescent intensity of the EpCAM specific PE.

Supplemental Figure 1 A. EpCAM Gating Strategy Top Row: Histogram showing unstained BT474 cells with low fluorescent intensity of the EpCAM specific PE.
Supplementary Figure 1. Clusters of orthologous groups (COGs) changes between MRSA CF-96 and CF-09 (A) Biological process.

Supplementary Figure 1. Clusters of orthologous groups (COGs) changes between MRSA CF-96 and CF-09 (A) Biological process.
Supplementary figure 1 Surface marker expression in % days A B Supplementary figure 1: Characterization of dmECFC and hECFC. ECFC clones showed a typical.

Supplementary figure 1 Surface marker expression in % days A B Supplementary figure 1: Characterization of dmECFC and hECFC. ECFC clones showed a typical.
Supplementary Figure.1 NF- κ B p65 / β- actin protein ** ID8HM-1 1 2 3 ** * * * β-actin ID8 HM-1 +CPA(0.7uM)non-treat+CPA(7uM)+CPA(70uM) NF-κB p65 β-actin.

Supplementary Figure.1 NF- κ B p65 / β- actin protein ** ID8HM ** * * * β-actin ID8 HM-1 +CPA(0.7uM)non-treat+CPA(7uM)+CPA(70uM) NF-κB p65 β-actin.
SKOV3 ~44% SKBR3 ~6% SiHa ~89% CaSki i ~67% HeLa ~89% Supplementary Figure 1 Huisman et al Supplementary Figure 1. DNA methylation status of the EPB41L3.

SKOV3 ~44% SKBR3 ~6% SiHa ~89% CaSki i ~67% HeLa ~89% Supplementary Figure 1 Huisman et al Supplementary Figure 1. DNA methylation status of the EPB41L3.
Supplementary Table S1 Clinical exposure for palbociclib, fulvestrant and chemotherapeutic agents used in this study. Palbociclib (1)*Paclitaxel (2)*Doxorubicin.

Supplementary Table S1 Clinical exposure for palbociclib, fulvestrant and chemotherapeutic agents used in this study. Palbociclib (1)*Paclitaxel (2)*Doxorubicin.
Main Figures and Tables. Figure 1 Strategy (shall we make a strategy figure here?? ）

Main Figures and Tables. Figure 1 Strategy (shall we make a strategy figure here?? ）
KS + Ima + Zvad % of positive cells (ANV+) Cells positive for SA-β-gal (%) Cells positive for SA-β-gal (%) % of positive cells (ANV+) Supplementary Figure.

KS + Ima + Zvad % of positive cells (ANV+) Cells positive for SA-β-gal (%) Cells positive for SA-β-gal (%) % of positive cells (ANV+) Supplementary Figure.
Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.

Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.
Figure Molecular Biology of the Cell (© Garland Science 2008)

Figure Molecular Biology of the Cell (© Garland Science 2008)
Figure 14-1 Molecular Biology of the Cell (© Garland Science 2008)

Figure 14-1 Molecular Biology of the Cell (© Garland Science 2008)
Glioma-derived soluble factor(s) enhance IL-10 signaling.

Glioma-derived soluble factor(s) enhance IL-10 signaling.
Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.

Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.
Supplemental Figure S1 KHK2805 KM8188 KM8188/113F(-f)

Supplemental Figure S1 KHK2805 KM8188 KM8188/113F(-f)

Similar presentations

Ads by Google